Stay updated on Pembrolizumab with BCG in HR NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.
Latest updates to the Pembrolizumab with BCG in HR NMIBC Clinical Trial page
- Check6 days agoChange DetectedNew entries were added on November 22 and November 26, 2024, while entries from November 14 and November 18, 2024, were removed.SummaryDifference0.1%
- Check13 days agoChange DetectedThe Institute of Science Tokyo Hospital has been added as a new site, while numerous study coordinator contact details have been removed, indicating a significant update in site management and contact information.SummaryDifference14%
- Check34 days agoChange DetectedThe website has been updated from version v2.11.2 to v2.12.1.SummaryDifference0.1%
- Check52 days agoChange DetectedNew study numbers and definitions related to carcinoma in situ (CIS) response metrics have been added, while similar entries from previous dates have been removed.SummaryDifference0.6%
- Check60 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
- Check74 days agoChange DetectedThe latest update includes a new study with 206 participants and revisions to site information in Coimbra, Portugal, while previous entries have been removed, including a study with 209 participants and earlier site details.SummaryDifference1%
Stay in the know with updates to Pembrolizumab with BCG in HR NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.